Health ConditionsFibromyalgia is a disorder of pain processing characterized by chronic widespread pain, fatigue, and disturbances in sleep, cognition, and mental health. In 1994, the 10th revision of the International Classification of Diseases (ICD-10) listed fibromyalgia under "diseases of the musculoskeletal system and connective tissue," and the WHO uses the term "disorder" to imply the existence of a clinically recognizable set of symptoms or behaviors associated in most cases with distress and interference with personal functions.
Fibromyalgia is characterized by chronic widespread pain, unrefreshing sleep, physical exhaustion, and cognitive difficulties, and it occurs in all populations throughout the world, with a prevalence between 2% and 4% in general populations. It is considered the third most common musculoskeletal disorder globally, following lower back pain and osteoarthritis, and is more prevalent in women than in men; although it can occur at any age, it is most common between the ages of thirty and thirty-five.
Fibromyalgia syndrome (FMS) is a chronic condition causing pain, stiffness, and tenderness of the muscles, tendons, and joints, and is also characterized by restless sleep, tiredness, fatigue, anxiety, depression, and disturbances in bowel functions. The painful tissues involved are not accompanied by tissue inflammation; despite potentially disabling body pain, patients with fibromyalgia do not develop tissue damage or deformity, and the pain is generally widespread, involving both sides of the body.
Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, often accompanied by fatigue, cognitive dysfunction, a variety of somatic complaints, and psychiatric disturbances such as depression and anxiety. These symptoms can exhibit variation not only between different patients but also in the same patient during the course of the disease.
Fibromyalgia is a disorder of pain regulation in which central sensitization — altered pain processing in the central nervous system — has a key role in its pathophysiology. Strong evidence indicates that cardinal pain symptoms of fibromyalgia may be due to alterations in central processing of sensory input, along with aberrations in the endogenous inhibition of pain. Only healthy persons showed evidence of endogenous opioid release in brain regions involved in pain processing and innervated by dopamine receptors, suggesting that both central augmentation of sensory input and diminished function of central pain inhibitory systems contribute to the abnormal pain sensitivity and persistent pain experienced by fibromyalgia patients.
Although the pathophysiology and etiopathogenesis remain largely unknown, three underlying processes have been investigated: central sensitization, associated with an increase in the release of both excitatory and inhibitory neurotransmitters; peripheral sensitization, involving alterations in peripheral nociceptor signaling; and inflammatory and immune mechanisms that develop concurrently with these processes.
Dysfunctional pain processing may be influenced by exposure to physical or psychological stressors, abnormal biological reactions in the autonomic nervous system, and neuroendocrine responses. The pathophysiology of fibromyalgia involves family and genetic factors, environmental triggers, and abnormalities in the neuroendocrine and autonomic nervous systems.
Although fibromyalgia is not considered an inflammatory disorder, the interaction of immunological mechanisms with pain physiology has led to the identification of alterations in the levels of various cytokines. Along with genetic, environmental, and neurohormonal factors, research has confirmed the contribution of inflammation to the pathogenesis of fibromyalgia.
Fibromyalgia patients have depleted coenzyme Q10 levels in tissues (typically 40–50% of the normal level), together with increased levels of mitochondrial dysfunction, oxidative stress, and inflammation, both in adults and in children/adolescents. There is a consistent association between fibromyalgia and increased oxidative damage and reduced antioxidant defences.
Studies have shown that 28–59% of patients with fibromyalgia develop irritable bowel syndrome (IBS), while 32–77% of patients with an IBS diagnosis develop fibromyalgia. The shared pathophysiology of fibromyalgia and IBS focuses on the roles of immune dysfunction, gut dysbiosis, neurotransmitter imbalances, and disturbances in the gut–brain axis.
A systematic review revealed an increased frequency of fibromyalgia among patients with cutaneous diseases including psoriasis, chronic urticaria, contact allergy, acneiform disorders, hidradenitis suppurativa, and vitiligo. Speculative pathophysiological hypotheses based on the current literature include dysregulation of inflammatory and immunological pathways, an altered autonomic nervous system, and psychosocial distress.
Genetic research has shown familial aggregation of fibromyalgia and other related disorders such as major depressive disorder. Genetic, endocrine, psychological, and sleep disorders may influence the development of this pathology.
Exposure to physical or psychosocial stressors, as well as abnormal biological responses in the autonomic nervous system and neuroendocrine responses, may contribute to dysfunctional pain processing. The literature acknowledges a composite etiology, suggesting a combination of genetic, environmental, and psychological factors, but there is insufficient elucidation on how these factors interrelate.
As an affective spectrum disorder, fibromyalgia may share causal factors with a number of related and co-occurring pain conditions such as irritable bowel syndrome or temporomandibular disorder. Fibromyalgia may also occur concurrently with chronic inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and systemic lupus erythematosus.
Evidence is mounting that gut bacteria could play a role in chronic pain and specifically fibromyalgia, with the composition of the gut bacterial community being altered in individuals with fibromyalgia, showing an altered abundance of a small subset of bacterial species. Bacterial taxa reported to be depleted in fibromyalgia include Faecalibacterium prausnitzii, Bacteroides uniformis, and Prevotella copri; these alterations were independent of host and environmental factors such as diet, physical activity, medications, and other medical comorbidities. A 2026 systematic review found the overall certainty of the evidence to be low to moderate, with greater strength for β-diversity, short-chain fatty acids (SCFAs), and the clinical manifestations of pain, fatigue, mood disturbances, and cognitive dysfunction.
Fibromyalgia is a complex chronic condition of unknown etiology, and it has been proposed that an imbalance of nutritive components, including essential metal ions and vitamins, might play a critical role in its development. Low intakes of magnesium, vitamin C, and polyphenols, and high intakes of saturated fat and refined carbohydrates, have been observed in fibromyalgia patients.
Association with fibromyalgia: Six studies, of which two had the best quality evidence, found that patients with fibromyalgia have low levels of vitamin D compared to healthy controls. The level of activity of multiple inflammatory pathways associated with chronic pain, such as interleukin-4 and TGF-β1, is downregulated in vitamin D deficiency; vitamin D also suppresses TNF-α in astrocytes and microglia, which has been implicated in peripheral and central sensitization.
Scientific evidence from clinical studies: In systematic review data, two studies (n=313) found a statistically significant association between vitamin D deficiency and fibromyalgia, while two others (n=161) found none; two RCTs assessing the effect of vitamin D supplementation in a total of 80 subjects found conflicting results, with pain reduction in one and none in the other. A systematic review of 434 studies identified 14 that met eligibility criteria; three studies, of which two had the best quality evidence, confirmed a correlation between diffuse muscle pain and 25-hydroxyvitamin D (25OHD) deficiency. Conflicting results were obtained on the effect of vitamin D on pain or symptom control, with no clear consensus as to the role of supplementation in the management of fibromyalgia, though the results highlight an association between vitamin D deficiency and fibromyalgia. Current scientific evidence supports that vitamin D supplementation cannot be routinely recommended in fibromyalgia in daily clinical practice; however, vitamin D supplementation in cases with a high risk of developing vitamin D deficiency or documented profound hypovitaminosis D is considered appropriate.
Evidence strength: Preliminary to moderate. An association between vitamin D deficiency and fibromyalgia is replicated across multiple studies; RCT evidence for symptom improvement is conflicting and currently insufficient to support routine supplementation.
Proposed mechanism: Magnesium's ability to block NMDA receptors may help alleviate some types of fibromyalgia pain.
Scientific evidence from clinical studies: Magnesium supplements have been widely used by fibromyalgia patients in an attempt to control their symptoms, though the evidence basis for this practice has been scrutinized. In most trials that explored the effect of magnesium on fibromyalgia, magnesium was given alongside other interventions; only a few studies used magnesium as a single intervention, and none of these were designed as blinded randomized controlled studies, adding to the uncertainty about the role of magnesium in fibromyalgia. A literature review of 81 RCTs on magnesium treatment in pain identified only 2 RCTs in fibromyalgia specifically, and the level of evidence for the efficacy of magnesium in reducing pain is globally modest, with studies not very numerous in chronic pain. One randomized double-blind clinical trial found that magnesium improves mild-to-moderate stress and reduces the pain experience in fibromyalgia patients.
Evidence strength: Preliminary and inconsistent. Some studies report reduced magnesium levels in fibromyalgia patients and correlations with symptom severity; trial evidence for supplementation is weak due to small sample sizes, confounded designs, and lack of rigorous placebo controls.
Proposed mechanism: Both mitochondrial dysfunction and CoQ10 deficiency have been implicated in fibromyalgia pathophysiology. CoQ10 is an essential component of mitochondrial electron transport and plays a crucial role in cellular energy production and as an antioxidant; since mitochondrial dysfunction and oxidative stress have been implicated in the pathophysiology of fibromyalgia, CoQ10 supplementation has been hypothesized as potentially beneficial.
Scientific evidence from clinical studies: A randomized, double-blind, placebo-controlled trial evaluated forty days of CoQ10 supplementation (300 mg/day) in 20 fibromyalgia patients and found an important clinical improvement after CoQ10 versus placebo, showing a reduction in total FIQ score (p<0.001) and prominent reductions in pain (p<0.001), fatigue, and morning tiredness (p<0.01) subscales. A 3-month RCT in 89 people with fibromyalgia found that a supplement containing CoQ10, magnesium, and tryptophan improved sleep quality, but it was unclear whether it had any other benefits compared to placebo. Trials of selected bioactive compounds, such as coenzyme Q10, curcumin-based formulations, L-carnitine, and certain probiotics, suggest beneficial effects on symptoms, whereas others show little or no effect.
Evidence strength: Preliminary. The most cited positive RCT was small (n=20); findings are encouraging but require replication in larger, well-controlled trials before firm conclusions can be drawn.
Proposed mechanism: Patients with fibromyalgia have low melatonin secretion, which could explain the lack of restorative sleep — a predisposing factor in trigger point formation and dysfunction of pain modulation mechanisms. Melatonin is involved in the regulation of several physiological processes, including circadian rhythms, pain, mood, and oxidative as well as immunomodulatory balance.
Scientific evidence from clinical studies: Preliminary clinical studies have propounded that the administration of different doses of melatonin to patients with fibromyalgia can reduce pain levels and ameliorate mood and sleep disturbances. In one phase II randomized, double-dummy, controlled trial, melatonin increased the inhibitory endogenous pain-modulating system; melatonin alone or combined with amitriptyline was better than amitriptyline alone in improving pain on the VAS. Study results are not entirely consistent, possibly because some doses used (3–5 mg) have been relatively low.
Evidence strength: Preliminary. Mechanistic rationale is credible given documented melatonin dysregulation in fibromyalgia; positive signals from small trials warrant larger RCTs.
Traditional use: SAMe is not a botanical product and does not have a discrete traditional herbal use; it is a naturally occurring compound in the body involved in methylation reactions. Its investigation in fibromyalgia has been driven by modern biochemical and clinical research rather than historical herbal traditions.
Scientific evidence from clinical studies: SAMe is discussed as a supplement with potential benefits in fibromyalgia management through anti-inflammatory effects, modulation of neurotransmitters, and improvement of mitochondrial function. SAMe has appeared in multiple fibromyalgia supplement reviews as a candidate with serotonergic and anti-inflammatory properties relevant to pain and mood, though the volume of dedicated fibromyalgia RCT evidence remains limited.
Evidence strength: Weak to preliminary in the fibromyalgia-specific context. SAMe has stronger evidence in other conditions (depression, osteoarthritis); fibromyalgia-specific trial data are sparse.
Proposed mechanism: Acetyl-L-carnitine, a form of the amino acid carnitine, is involved in mitochondrial energy production and reducing oxidative stress; it modulates neurotransmitter activity, increases the activity of nerve growth factors, and appears to quiet pain signaling and inhibit pain sensitization.
Scientific evidence from clinical studies: In one 10-week trial, those receiving acetyl-L-carnitine had improvements in depression, musculoskeletal pain, and quality of life scores. Another RCT in 65 women with fibromyalgia compared 500 mg of oral acetyl-L-carnitine three times daily to duloxetine; after 12 weeks, improvements in pain, depressive symptoms, and general clinical status were seen in both groups. Acetyl-L-carnitine is discussed for its potential benefits in fibromyalgia management through anti-inflammatory effects, modulation of neurotransmitters, and improvement of mitochondrial function.
Evidence strength: Preliminary. Small RCTs show promising signal for pain and mood, but sample sizes are limited and direct comparators (active drugs) rather than true placebos have often been used.
Traditional use: Fish oils and omega-3-rich foods have been part of traditional coastal and Nordic diets for millennia, recognized empirically for their anti-inflammatory properties, though the specific concept of fibromyalgia did not exist in pre-modern medicine.
Scientific evidence: Omega-3 fatty acids are discussed for their potential benefits in fibromyalgia through anti-inflammatory effects and modulation of neurotransmitters. They are specifically included in a neuronutritional review as having potential benefits via anti-inflammatory effects in fibromyalgia. Direct fibromyalgia-specific RCT data on isolated omega-3 supplementation are limited; the evidence base is primarily mechanistic and observational.
Evidence strength: Weak in fibromyalgia-specific RCTs. Theoretical anti-inflammatory rationale is strong; large well-designed trials specific to fibromyalgia are lacking.
Traditional use: Turmeric (Curcuma longa) has been used for over 4,000 years in Ayurvedic and traditional Chinese medicine as an anti-inflammatory and analgesic agent, administered as a dietary spice and in medicinal preparations for musculoskeletal pain, joint conditions, and digestive complaints.
Scientific evidence: In a rat model of cobra venom-induced trigeminal neuralgia, curcumin (45 mg/kg twice daily for 28 days) alleviated pain behaviors and improved spatial memory by restoring neuronal integrity in the hippocampus. This is preclinical evidence only. Trials of curcumin-based formulations suggest beneficial effects on fibromyalgia symptoms, though others show little or no effect. A neuro-nutritional narrative review indicated that curcumin, alongside other interventions, may improve fibromyalgia symptoms.
Evidence strength: Weak for fibromyalgia specifically. Mechanistic and animal evidence is supportive; human fibromyalgia-specific RCT data remain scarce.
Proposed mechanism: 5-HTP is the immediate precursor to serotonin, a neurotransmitter involved in both pain modulation and sleep regulation. Fibromyalgia has been associated with altered serotonergic signaling, providing a biochemical rationale for this intervention.
Scientific evidence: Clinical trials have shown that 5-HTP is associated with improvements in anxiety, pain intensity, quality of sleep, fatigue, and tender points. The existing trials are small and date primarily from the 1990s, and the evidence requires updating with larger, better-controlled studies.
Evidence strength: Preliminary. Small older trials show consistent directional signals for symptom improvement; more rigorous modern trials are needed.
Scientific evidence: Adequate intake of magnesium, selenium, vitamin D, and vitamin B12 is considered important in the context of fibromyalgia. Putative mechanisms of vitamin B12's effect on the course of fibromyalgia have been described, and include its roles in neuronal myelination, neurotransmitter synthesis, and mitochondrial function. Clinical trials on vitamin B12 supplementation show promising results, though overall the role of these supplements remains controversial.
Evidence strength: Weak. Deficiency associations are documented; RCT evidence specific to fibromyalgia is limited.
Rationale: Emerging evidence suggests that gut microbiota alterations may contribute to fibromyalgia symptoms through immune dysregulation, neuroinflammation, and disruption of the gut–brain axis. This has prompted interest in probiotic interventions as a potential modulating strategy.
Scientific evidence: Clinical trials with probiotics show promising results, though the overall role of dietary supplements in fibromyalgia remains controversial. Nonpharmacological measures including dietary interventions have shown potential in small clinical trials.
Evidence strength: Preliminary. The gut microbiome–fibromyalgia connection is increasingly documented, but probiotic-specific RCT evidence remains sparse and of low certainty.
Adopting plant-based diets, particularly Mediterranean-type diets, has been linked to improvements in pain, fatigue, sleep, and gastrointestinal symptoms, as well as modest gains in quality of life. A study of 22 fibromyalgia patients revealed that a 16-week Mediterranean diet with or without high doses of tryptophan and magnesium led to several beneficial effects on emotional processing, decreased fatigue, anxiety, and depression, and reduced eating disorders and body image dissatisfaction, with significantly greater improvements especially in the Mediterranean diet plus supplements group.
The anti-inflammatory benefits of the low-FODMAP diet have shown promise in managing fibromyalgia symptoms and related gastrointestinal disorders. Given the high co-occurrence of irritable bowel syndrome with fibromyalgia, the low-FODMAP approach addresses gastrointestinal symptoms that may contribute to overall symptom burden.
There is a consistent association between fibromyalgia and increased oxidative damage and reduced antioxidant defences; adopting plant-based diets has been linked to improvements in pain, fatigue, sleep, and gastrointestinal symptoms. Cross-sectional data further suggest that diets with higher antioxidant potential may be associated with lower oxidative stress in fibromyalgia.
With regard to dietary interventions, the administration of olive oil, the replacement diet with ancient grains, low-calorie diets, the low-FODMAP diet, and the gluten-free diet have been studied in fibromyalgia. Evidence for these approaches is largely from small, preliminary trials.
Fibromyalgia patients with poor dietary quality have been found to have a higher body mass index, higher fat mass, lower muscle mass, and to experience more severe pain and fatigue; low intakes of magnesium, vitamin C, and polyphenols, and high intakes of saturated fat and refined carbohydrates, have also been observed.
Lifestyle modifications, including regular low-impact exercise, should be emphasized as core strategies for fibromyalgia symptom management. Given fibromyalgia's complex pathophysiology and the potential side effects of pharmacological treatments, exercise therapy is considered a key management component; evidence indicates that it alleviates pain, improves sleep, reduces fatigue and depressive symptoms, and ultimately contributes to better quality of life.
Standard exercise protocols typically include two to three sessions per week lasting 25–45 minutes at light-to-moderate intensity; low-impact activities such as walking, cycling, aquatic exercise, and elliptical training are preferred; meta-analytic data suggest that the most significant improvements in Fibromyalgia Impact Questionnaire scores occur with programs lasting 13 to 24 weeks or longer.
A meta-analysis of 42 primary studies revealed a moderate statistically significant effect of exercise-based interventions on sleep quality (SMD = –0.46); subgroup analyses showed significant effects for mind–body exercises and combined exercises, but not for aerobic or strength exercises in isolation.
Compared with placebo or sham treatments, there was some evidence that exercise — specifically land-based aerobic exercise training combined with flexibility training and aquatic-based aerobic exercise training — may improve sleep quality in fibromyalgia. There is a low level of certainty surrounding the effectiveness of interventions for the management of sleep problems in fibromyalgia, but some forms of exercise training appear more likely to provide an improvement in sleep quality.
Nonpharmacological measures, including lifestyle interventions such as diet, exercise, regular sleep, and stress reduction, have been shown to modulate the composition of the gut microbiome. Interestingly, despite the high prevalence of IBS among individuals with fibromyalgia, specific alterations in the composition of the gut microbiome were observed independently of those associated with IBS, and the relative abundance of certain bacterial taxa was associated with symptom severity.
Fibromyalgia patients with poor nutritional quality have been found to have a higher body mass index and fat mass, as well as lower muscle mass, and to experience more severe pain and fatigue. While causation is not established, this observational association underscores the potential interaction between body composition and symptom burden.
Analysis of the literature shows that the role of dietary supplements in fibromyalgia remains controversial, although clinical trials with vitamin D, magnesium, iron, and probiotics show promising results. This underscores the importance of considering nutritional approaches as a component of fibromyalgia management, while advocating for further research and clinical trials to establish comprehensive dietary guidelines and optimize management strategies.
Due to factors such as methodological shortcomings of existing studies, and the lack of evidence on individual modalities, it is difficult to draw definitive conclusions as to which rehabilitation approach is most appropriate in fibromyalgia syndrome.
5-HTP is a serotonin precursor that has been studied in both double-blind placebo-controlled and open-label trials specifically in fibromyalgia patients. A 1990 double-blind RCT (n=50) found all clinical parameters — tender points, pain intensity, morning stiffness, sleep, and anxiety — were significantly improved versus placebo. A 90-day open study confirmed sustained efficacy. Low serotonin metabolism is a recognized feature of fibromyalgia pathophysiology.
FM may be associated with carnitine deficits affecting mitochondrial energy metabolism. A double-blind multicenter RCT (Rossini et al., Clin Exp Rheumatol, 2007) in 102 FM patients found acetyl-L-carnitine improved musculoskeletal pain, depression, and quality-of-life scores versus placebo over 10 weeks. Additional RCTs comparing acetyl-L-carnitine with duloxetine and as add-on to standard care have supported modest benefit for pain and mood.
Alpha-lipoic acid is a potent antioxidant investigated in FM because of the documented role of oxidative stress in FM pathophysiology and ALA's proven efficacy in painful neuropathy. A double-blind, randomized, placebo-controlled crossover RCT (IMPALA Trial, registered ISRCTN58259979) was designed to evaluate ALA at 1,800 mg/day in FM patients. A second RCT (CADENCE) studied ALA in combination with pregabalin. A 2025 systematic review specifically listed ALA among nutraceuticals explored for FM.
D-ribose at 15 g/day was studied in 41 fibromyalgia/CFS patients (2006 pilot) and 257 patients (2012 multicenter trial), both reporting significant improvements in pain, energy, sleep, and well-being. Both studies were open-label without placebo controls. Fibromyalgia is associated with impaired cellular energy metabolism, which provides a mechanistic rationale.
Topical capsaicin (0.025%) has been identified in dietary supplement reviews as having evidence for joint tenderness relief in FM. A review of dietary supplements for FM treatment noted topical capsaicin showed benefit for joint tenderness, though not for overall FM pain. The Arthritis Foundation notes many studies showing capsaicin effectively reduces pain from FM among other conditions. Capsaicin depletes substance P from sensory nerve endings, reducing nociceptive signaling.
Pilot RCTs have evaluated topical capsaicin as adjunctive therapy for fibromyalgia pain. A pilot study by McCarty et al. (Semin Arth Rheum, 1994) demonstrated pain relief. PubMed identifies capsaicin as a topical pain reliever evaluated in RCTs for fibromyalgia. Evidence is preliminary but qualifies as scientific.
A pilot clinical study assessed topical capsaicin for fibromyalgia pain and found improvements in pain scores, providing preliminary clinical evidence for this application. The mechanism — substance P depletion in sensitized central and peripheral nociceptive circuits — is pharmacologically plausible.
Topical capsaicin has been studied for fibromyalgia-related muscle pain in controlled trials. A pilot study published in Seminars in Arthritis and Rheumatism (McCarty et al., 1994) and several subsequent double-blind trials showed significant pain reduction from topical capsaicin application in fibromyalgia patients.
A pilot double-blind, placebo-controlled RCT at Virginia Commonwealth University evaluated chlorella in 55 fibromyalgia patients and found potential for symptom relief and quality-of-life improvement, with authors concluding that larger trials are warranted.
CoQ10 deficiency and mitochondrial dysfunction have been documented in FM patients, with tissue CoQ10 levels reportedly 40–50% below normal. A randomized double-blind placebo-controlled trial in 20 FM patients found 300 mg/day CoQ10 for 40 days significantly reduced FIQ scores, pain, fatigue, and tender points versus placebo. A separate randomized crossover study in 22 female FM patients showed CoQ10 improved pain-related outcomes by 24–37% and reduced sleep disturbance by ~33%.
A 16-week randomized, double-blind, placebo-controlled trial demonstrated that creatine supplementation improved muscle function in fibromyalgia patients, with an 80.3% increase in intramuscular phosphorylcreatine. An earlier open-label study reported improvements in pain, quality of life, and sleep. Evidence base is small but clinical in design.
Curcumin (from turmeric) has been listed in multiple recent systematic reviews and narrative reviews as a nutraceutical investigated for FM symptom management, primarily via anti-inflammatory and antioxidant mechanisms. A 2025 narrative review (PMC) cited curcumin among supplements potentially improving FM symptoms, and a 2025 Drug Topics review identified curcumin among key nutraceuticals for FM pain. Preclinical neuropathic pain models show curcumin alleviates pain behaviors and restores neuronal integrity.
FM patients have been hypothesized to have altered muscle adenine nucleotide metabolism, depleting cellular ATP. An open-label pilot study (Teitelbaum et al., J Altern Complement Med, 2006) in 41 FM and/or chronic fatigue syndrome patients treated with D-ribose 5 g three times daily found significant improvements across all five VAS categories: energy, sleep, mental clarity, pain intensity, and well-being, with approximately 66% experiencing significant improvement and average energy increase of 45%. A case report also documented symptom reduction in an FM patient.
Multiple studies show fibromyalgia patients frequently have lower magnesium levels, and supplementation has demonstrated benefit in some trials. A 2021 literature review (Boulis et al., Sage Journals) surveyed multiple correlational and interventional studies. A 2022 double-blind RCT found magnesium significantly reduced mild/moderate stress and pain severity in FM patients versus placebo. Magnesium citrate combined with amitriptyline has also been evaluated as adjunct therapy.
FM patients have documented lower nocturnal melatonin secretion. A 2019 systematic review of four controlled and uncontrolled studies in 98 FM patients concluded all studies reported positive effects of melatonin on FM symptoms including pain, sleep, fatigue, and tender point count, with no major adverse events. A 2010 double-blind placebo-controlled RCT in 101 FM patients found melatonin alone or combined with fluoxetine significantly reduced total FIQ scores.
An open pilot study (Edwards et al., J Nutr Environ Med, 2001) investigated CMO in 13 fibromyalgia patients over 21 days. Ten patients completed the study; mean pain, fatigue, and sleep disturbance scores improved meaningfully, with five showing good response. Wikipedia confirms this pilot study as evidence of potential benefit, though notes low evidence quality and the absence of a follow-up placebo-controlled trial.
PEA is an endogenous fatty acid amide that acts on the endocannabinoid system and downregulates mast cell and glial cell activity implicated in FM pathophysiology. Observational clinical investigations in FM patients found micronized and ultra-micronized PEA reduced pain intensity and improved quality of life. A 2025 retrospective comparative study in 86 FM patients found ALC+PEA as add-on therapy produced a significant FIQR reduction of 19 points (p<0.001) versus no change in standard-care-only controls.
Pregnenolone has been proposed as a neurosteroid relevant to fibromyalgia via its analgesic and anti-fatigue properties. One case study documents significant fibromyalgia pain relief with hormonal support including pregnenolone. Its analgesic RCT results in chronic low back pain support its broader candidacy for neurosteroid-mediated pain conditions.
SAMe is among the most historically studied nutraceuticals for FM, with a review of seven clinical trials finding benefit for FM-related depression and tender point pain severity. A 1987 double-blind crossover study in 17 FM patients found SAMe significantly reduced the number of trigger points (p<0.02) and improved depression scores versus placebo. Additional randomized trials, including intravenous and oral administration studies, supported these findings.
Serratiopeptidase is listed in clinical prescribing references as an indicated agent for fibromyalgia, based on its anti-inflammatory and analgesic mechanisms. It is included among SRP clinical applications in the AJPCR review and RxList. However, no dedicated fibromyalgia RCT has been identified in the peer-reviewed literature; evidence is based on indication listings and mechanistic extrapolation from anti-inflammatory data.
D-series resolvins reduced pain and depressive symptoms in a preclinical fibromyalgia model. A human clinical trial of SPM precursors showed significant improvements in pain and quality of life in adults with chronic pain including fibromyalgia-type symptoms. Fibromyalgia is among conditions for which SPM efficacy has been documented in preclinical models.
Vitamin D deficiency is commonly found in FM patients and correlates inversely with pain severity and FIQ scores. A 2025 systematic review and meta-analysis found vitamin D supplementation significantly reduced pain levels compared to control, with effect sizes of SMD −0.85 on NRS/VAS (p=0.0148) and SMD −0.87 on FIQ scale (p=0.0115). A 2017 meta-analysis also concluded vitamin D is a determinant factor in FM.
Vitamin D3 (cholecalciferol) is the form most commonly used in clinical studies evaluating vitamin D supplementation for FM. Evidence base is the same as for vitamin D: meta-analyses confirm association of deficiency with FM symptom severity and significant pain reduction with supplementation in deficient patients. The 2025 systematic review and meta-analysis found significant FM pain reduction (SMD −0.85 to −0.87) with vitamin D supplementation.
Cat's claw is listed in modern herbal medicine references as a remedy for fibromyalgia, attributed to its anti-inflammatory and analgesic properties. Multiple integrative medicine sources recommend it for chronic conditions involving neuroinflammation such as fibromyalgia. No clinical trials specifically for fibromyalgia exist.
Go back